In summary, the downregulation of ephrin-B2 disrupts critical signaling pathways in VSMCs and endothelial cells, leading to vascular wall defects, increased inflammation, and impaired angiogenesis, all of which contribute to the progression and potential rupture of AAAs. The gene discussed is EFNB2; the disease is achalasia-alacrima syndrome.